GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (OTCPK:STAB) » Definitions » Revenue per Share

Statera BioPharma (Statera BioPharma) Revenue per Share : $0.00 (TTM As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Revenue per Share?

Statera BioPharma's revenue per share for the three months ended in Sep. 2022 was $0.00. Statera BioPharma's revenue per share for the trailing twelve months (TTM) ended in Sep. 2022 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Statera BioPharma's Revenue per Share or its related term are showing as below:

STAB's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.65
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Statera BioPharma Revenue per Share Historical Data

The historical data trend for Statera BioPharma's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma Revenue per Share Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Revenue per Share
- - -

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Statera BioPharma's Revenue per Share

For the Biotechnology subindustry, Statera BioPharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Statera BioPharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's PS Ratio falls into.



Statera BioPharma Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Statera BioPharma's Revenue Per Share for the fiscal year that ended in Dec. 2021 is calculated as

Revenue Per Share (A: Dec. 2021 )=Revenue (A: Dec. 2021 )/Shares Outstanding (Diluted Average) (A: Dec. 2021 )
=0/35.110
=0.00

Statera BioPharma's Revenue Per Share for the quarter that ended in Sep. 2022 is calculated as

Revenue Per Share (Q: Sep. 2022 )=Revenue (Q: Sep. 2022 )/Shares Outstanding (Diluted Average) (Q: Sep. 2022 )
=0/50.234
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Statera BioPharma  (OTCPK:STAB) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Statera BioPharma Revenue per Share Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Statera BioPharma (Statera BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.
Executives
Satishchandran Chandrasekhar director 167 CARMELA COURT, JUPITER FL 33478
Taunia Markvicka director, officer: Chief Operating Officer 2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Robert Buckheit officer: Chief Technology Officer C/O CYTOCOM INC., 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Mcavoy Cozette M. officer: Chief Legal Officer 2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Michael K Handley director, officer: President and CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Clifford Selsky officer: Chief Medical Officer 2537 RESEARCH BOULERVARD, SUITE 201, FORT COLLINS CO 80526
Peter Aronstam officer: Chief Financial Officer 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Steve K Barbarick director TRACTOR SUPPLY COMPANY, 5401 VIRGINIA WAY, BRENTWOOD TN 37027
Christopher Zosh officer: Vice President of Finance C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Ivan Fedyunin director 73 HIGH STREET, BUFFALO NY 14203
John Edward Szydlo officer: Principal Financial Officer 73 HIGH STREET, BUFFALO NY 14203
Alexander Andryushechkin director 73 HIGH STREET, BUFFALO NY 14203
Daniil Talyanskiy director 73 HIGH STREET, BUFFALO NY 14203
Lea Verny director 73 HIGH STREET, BUFFALO NY 14203
Alexey Nechaev director 73 HIGH STREET, BUFFALO NY 14203

Statera BioPharma (Statera BioPharma) Headlines

From GuruFocus